Type 1 diabetes
Conditions
Brief summary
Change in fasting residual β cell (C-peptide) function, baseline to 12 months.
Detailed description
Change in fasting C-peptide levels, baseline to 6 months., Change in HbA1c, baseline to 12 months., Change in insulin requirements, baseline to 12 months (measured as total insulin dose per kg body weight per day as a mean for the last 14 days)., Time-In-Range (3.9-10.0 mmol/L) of continuous glucose monitoring over 14 days at 12 months., Percent coefficient of variation of glucose (%CV) over 14 days at 12 months.
Interventions
DRUG0.9% sodium chloride for intra muscular injection from hospital stock
DRUGVaxigrip Tetra
DRUGinactivated)
Sponsors
Aarhus University Hospital
Eligibility
Sex/Gender
All
Age
0 Years to 17 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in fasting residual β cell (C-peptide) function, baseline to 12 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in fasting C-peptide levels, baseline to 6 months., Change in HbA1c, baseline to 12 months., Change in insulin requirements, baseline to 12 months (measured as total insulin dose per kg body weight per day as a mean for the last 14 days)., Time-In-Range (3.9-10.0 mmol/L) of continuous glucose monitoring over 14 days at 12 months., Percent coefficient of variation of glucose (%CV) over 14 days at 12 months. | — |
Countries
Denmark
Outcome results
None listed